MedTrace Logo

The Efficacy and Safety of a Single-Dose Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis

NCT07487038 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 133

Last updated 2026-04-29

No results posted yet for this study

Summary

HA therapy typically consists of several intra-articular injections administered at weekly intervals. A single-dose IA-HA treatment offers patients and physicians a treatment option that involves both lower costs and fewer clinic visits. Furthermore, considering the administration procedure, we believe that single-dose therapy helps reduce the risk of potential side effects.

In light of this information, our study aims to retrospectively evaluate the efficacy and safety of HA in patients with symptomatic knee OA who have received a single-dose intra-articular HA injection.

Conditions

  • Knee Osteoarthristis
  • Hyaluronic Acid

Interventions

DEVICE

Intra-articular hyaluronic acid injection

A single-dose intra-articular hyaluronic acid (HA) injection (Re-Cross by Reviscon-containing 88 mg of sodium hyaluronate in 4.0 ml) was administered to patients with symptomatic knee osteoarthritis using the lower lateral patellar approach with the knee flexed at 90 degrees.

Sponsors & Collaborators

  • Fatih Sultan Mehmet Training and Research Hospital

    lead OTHER

Principal Investigators

  • Yunus Emre DOĞAN, MD · Istanbul Fatih Sultan Mehmet Training and Research Hospital

  • Aslınur KELEŞ ERCİŞLİ, MD · Istanbul Fatih Sultan Mehmet Training and Research Hospital

  • Arzu ATICI, MD, Assoc. Prof. · Istanbul Fatih Sultan Mehmet Training and Research Hospital

  • Meryem YILMAZ KAYSIN, MD · Istanbul Fatih Sultan Mehmet Training and Research Hospital

  • İlknur AKTAŞ, MD, Prof. · Istanbul Fatih Sultan Mehmet Training and Research Hospital

  • Feyza ÜNLÜ ÖZKAN, MD, Prof. · Istanbul Fatih Sultan Mehmet Training and Research Hospital

  • Aylin REZVANİ, MD, Prof. · Medipol University

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-05-15
Completion
2026-05-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07487038 on ClinicalTrials.gov